Skip to main content
Erschienen in: Rheumatology International 1/2021

20.09.2019 | Case Based Review

The same mutation in a family with adenosine deaminase 2 deficiency

verfasst von: Betul Sozeri, Gozde Ercan, Ozlem Akgun Dogan, Jale Yıldız, Ferhat Demir, Levent Doğanay

Erschienen in: Rheumatology International | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

The deficiency of adenosine deaminase 2 (DADA2) has recently been defined as a monogenetic autosomal recessive autoinflammatory disease. DADA2 is mainly characterized by high fever, livedo racemose, early-onset stroke, mild immunodeficiency and clinically polyarteritis nodosa (PAN)-like symptoms. Mutations in CECR1 (cat eye syndrome chromosome region, candidate 1) are responsible for DADA2. Livedoid racemose, lacunar infarct due to involvement in small vessel of the central nervous system, peripheral neuropathy, digital ulcers and loss of fingers are predominantly seen in the disease which could progress to end-stage organ failure and death in some patients. A wide spectrum of severity in phenotype as well as in the age of onset has been reported in the literature. This phenotypic variability is also found in our clinical practice even in patients with the same mutation. Here, we present a family diagnosed with DADA2, with the previously reported p.Gly47Arg mutation in CECR1.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV et al (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370(10):911–920CrossRef Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV et al (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370(10):911–920CrossRef
2.
Zurück zum Zitat Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370(10):921–931CrossRef Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370(10):921–931CrossRef
3.
Zurück zum Zitat Meyts I, Aksentijevich I (2018) Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 38(5):569–578CrossRef Meyts I, Aksentijevich I (2018) Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 38(5):569–578CrossRef
4.
Zurück zum Zitat Hershfield MS (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35(1):25–30CrossRef Hershfield MS (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35(1):25–30CrossRef
5.
Zurück zum Zitat Minguet S, Dopfer EP, Pollmer C, Freudenberg MA, Galanos C, Reth M et al (2008) Enhanced B-cell activation mediated by TLR4 and BCR crosstalk. Eur J Immunol 38(9):2475–2487CrossRef Minguet S, Dopfer EP, Pollmer C, Freudenberg MA, Galanos C, Reth M et al (2008) Enhanced B-cell activation mediated by TLR4 and BCR crosstalk. Eur J Immunol 38(9):2475–2487CrossRef
6.
Zurück zum Zitat Majumdar S, Aggarwal BB (2003) Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene 22(8):1206–1218CrossRef Majumdar S, Aggarwal BB (2003) Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene 22(8):1206–1218CrossRef
7.
Zurück zum Zitat Simmonds HA, Webster DR, Perrett D, Reiter S, Levinsky RJ (1982) Formation and degradation of deoxyadenosine nucleotides in inherited adenosine deaminase deficiency. Biosci Rep 2(5):303–314CrossRef Simmonds HA, Webster DR, Perrett D, Reiter S, Levinsky RJ (1982) Formation and degradation of deoxyadenosine nucleotides in inherited adenosine deaminase deficiency. Biosci Rep 2(5):303–314CrossRef
8.
Zurück zum Zitat Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G (2010) Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 88(2):279–290CrossRef Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G (2010) Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 88(2):279–290CrossRef
9.
Zurück zum Zitat Iwaki-Egawa S, Yamamoto T, Watanabe Y (2006) Human plasma adenosine deaminase 2 is secreted by activated monocytes. Biol Chem 387(3):319–321CrossRef Iwaki-Egawa S, Yamamoto T, Watanabe Y (2006) Human plasma adenosine deaminase 2 is secreted by activated monocytes. Biol Chem 387(3):319–321CrossRef
10.
Zurück zum Zitat Schrader WP, Pollara B, Meuwissen HJ (1978) Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci USA 75(1):446–450CrossRef Schrader WP, Pollara B, Meuwissen HJ (1978) Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci USA 75(1):446–450CrossRef
11.
Zurück zum Zitat Van Eyck L, Jr Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L et al (2015) Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol 135(1):283–287CrossRef Van Eyck L, Jr Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L et al (2015) Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol 135(1):283–287CrossRef
12.
Zurück zum Zitat Bae MJ, Ryu S, Kim HJ, Cha SI, Kim CH, Lee J (2017) Mycobacterium tuberculosis ESAT6 and CPF10 induce adenosine deaminase 2 mRNA expression in monocyte-derived macrophages. Tuberc Respir Dis (Seoul) 80(1):77–82CrossRef Bae MJ, Ryu S, Kim HJ, Cha SI, Kim CH, Lee J (2017) Mycobacterium tuberculosis ESAT6 and CPF10 induce adenosine deaminase 2 mRNA expression in monocyte-derived macrophages. Tuberc Respir Dis (Seoul) 80(1):77–82CrossRef
13.
Zurück zum Zitat Valdes L, San Jose E, Alvarez D, Valle JM (1996) Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Eur Respir J 9(4):747–751CrossRef Valdes L, San Jose E, Alvarez D, Valle JM (1996) Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Eur Respir J 9(4):747–751CrossRef
14.
Zurück zum Zitat Sari RA, Taysi S, Yilmaz O, Bakan N (2003) Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. Clin Exp Rheumatol 21(1):87–90PubMed Sari RA, Taysi S, Yilmaz O, Bakan N (2003) Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. Clin Exp Rheumatol 21(1):87–90PubMed
15.
Zurück zum Zitat Fernandez E, Rodrigo L, Riestra S, Carcia S, Gutierrez F, Ocio G (2000) Adenosine deaminase isoenzymes and neopterin in liver cirrhosis. J Clin Gastroenterol 30(2):181–186CrossRef Fernandez E, Rodrigo L, Riestra S, Carcia S, Gutierrez F, Ocio G (2000) Adenosine deaminase isoenzymes and neopterin in liver cirrhosis. J Clin Gastroenterol 30(2):181–186CrossRef
16.
Zurück zum Zitat Gasparyan AY, Ayvazyan L, Blackmore H (2011) Kitas GD Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRef Gasparyan AY, Ayvazyan L, Blackmore H (2011) Kitas GD Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRef
17.
Zurück zum Zitat Ozen S, Bilginer Y, Batu ED, Taşkıran E, Özkara HA, Ünal Ş, Güleray N, Erden A, Karadağ Ö, Gümrük F, Çetin M, Sönmez HE, Ayvaz DÇ, Tezcan I (2019) A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2 Subtitle: Deficiency of adenosine deaminase. J Rheumatol. https://doi.org/10.3899/jrheum.181384CrossRefPubMed Ozen S, Bilginer Y, Batu ED, Taşkıran E, Özkara HA, Ünal Ş, Güleray N, Erden A, Karadağ Ö, Gümrük F, Çetin M, Sönmez HE, Ayvaz DÇ, Tezcan I (2019) A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2 Subtitle: Deficiency of adenosine deaminase. J Rheumatol. https://​doi.​org/​10.​3899/​jrheum.​181384CrossRefPubMed
18.
Zurück zum Zitat Garg N, Kasapcopur O, Foster J 2nd, Barut K, Tekin A, Kizilkilic O et al (2014) Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr 173(6):827–830CrossRef Garg N, Kasapcopur O, Foster J 2nd, Barut K, Tekin A, Kizilkilic O et al (2014) Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr 173(6):827–830CrossRef
19.
Zurück zum Zitat Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M et al (2015) A case series of adenosine deaminase 2- deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol 42(8):1532–1534CrossRef Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M et al (2015) A case series of adenosine deaminase 2- deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol 42(8):1532–1534CrossRef
20.
Zurück zum Zitat Trotta L, Martelius T, Siitonen T, Hautala T, Hamalainen S, Juntti H et al (2018) ADA2 deficiency: clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol 141(1534–1537):e8 Trotta L, Martelius T, Siitonen T, Hautala T, Hamalainen S, Juntti H et al (2018) ADA2 deficiency: clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol 141(1534–1537):e8
21.
Zurück zum Zitat Sundin M, Marits P, Nierkens S, Kolios AGA, Nilsson J (2019) "Immune" thrombocytopenia as key feature of a novel ADA2 deficiency variant: implication on differential diagnostics of ITP in children. J Pediatr Hematol Oncol 41(2):155–157CrossRef Sundin M, Marits P, Nierkens S, Kolios AGA, Nilsson J (2019) "Immune" thrombocytopenia as key feature of a novel ADA2 deficiency variant: implication on differential diagnostics of ITP in children. J Pediatr Hematol Oncol 41(2):155–157CrossRef
22.
Zurück zum Zitat Van Eyck L, Liston A, Wouters C (2014) Mutant ADA2 in vasculopathies. N Engl J Med 371(5):480PubMed Van Eyck L, Liston A, Wouters C (2014) Mutant ADA2 in vasculopathies. N Engl J Med 371(5):480PubMed
23.
Zurück zum Zitat Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S et al (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 68(9):2314–2322CrossRef Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S et al (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 68(9):2314–2322CrossRef
24.
Zurück zum Zitat Ombrello ASD, Hoffmann P, Jones A, Barham B, Barron K, Flegel W et al (2015) The deficiency of adenosine deaminase type 2-results of therapeutic intervention. Pediatr Rheumatol 13(1):O40CrossRef Ombrello ASD, Hoffmann P, Jones A, Barham B, Barron K, Flegel W et al (2015) The deficiency of adenosine deaminase type 2-results of therapeutic intervention. Pediatr Rheumatol 13(1):O40CrossRef
25.
Zurück zum Zitat Bucciol G, Delafontaine S, Segers H, Bossuyt X, Hershfield MS, Moens L et al (2017) Hematopoietic stem cell transplantation in ADA2 deficiency: early restoration of ADA2 enzyme activity and disease relapse upon drop of donor chimerism. J Clin Immunol 37(8):746–750CrossRef Bucciol G, Delafontaine S, Segers H, Bossuyt X, Hershfield MS, Moens L et al (2017) Hematopoietic stem cell transplantation in ADA2 deficiency: early restoration of ADA2 enzyme activity and disease relapse upon drop of donor chimerism. J Clin Immunol 37(8):746–750CrossRef
26.
Zurück zum Zitat Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ et al (2016) Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford) 55(5):902–910CrossRef Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ et al (2016) Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford) 55(5):902–910CrossRef
27.
Zurück zum Zitat Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M et al (2017) ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis 76(10):1648–1656CrossRef Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M et al (2017) ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis 76(10):1648–1656CrossRef
Metadaten
Titel
The same mutation in a family with adenosine deaminase 2 deficiency
verfasst von
Betul Sozeri
Gozde Ercan
Ozlem Akgun Dogan
Jale Yıldız
Ferhat Demir
Levent Doğanay
Publikationsdatum
20.09.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 1/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04444-z

Weitere Artikel der Ausgabe 1/2021

Rheumatology International 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.